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Case Report
Serum eosinophil cationic protein levels can be useful
for predicting acute exacerbation of asthma
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Junzaburo Kabe
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ABSTRACT
We report on a case in which five consecutive exacer-
bations of asthma were monitored by following serum
eosinophil cationic protein (ECP) levels. The serum ECP
level correlated well with each exacerbation and tended
to increase even before the exacerbations of asthma
became apparent. This case shows that serum levels of
ECP can be useful markers of disease activity and may
also be predictive markers for acute exacerbation.
Keywords: asthma attack, eosinophil cationic protein,
predictive marker.
INTRODUCTION
One of the important causes of bronchial asthma (BA) is
airway inflammation, characterized by the infiltration of
eosinophils.' Increased levels of eosinophil proteins, such
as eosinophil cationic protein (ECP) and eosinophil
protein X (EPX) in bronchoalveolar lavage fluid (BALF) and
serum in asthmatic patients have also been reported.?
Other data show that serum ECP levels, in contrast with
the total eosinophil count, are correlated with the fluctua-
tion of pulmonary function related to exocerbotion.v"
Thus, eosinophil proteins in serum or BALF reflect the acti-
vation of eosinophils more accurately than the eosinophil
count itself. We have measured the serum ECP level,
eosinophil count, peak expiratory flow rate (PEF) and pul-
monary function in several asthmatic patients. In the
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present paper we report on a case in which five consecu-
tive exacerbations were monitored over a period of more
than 1 year and in whom the serum ECP level correlated
well with asthma exacerbation and tended to increase
before the appearance of clinical symptoms.
CASE REPORT
A 62-year-old woman with non-atopic asthma presented
with symptoms for the first time in 1975. Since 1989, her
symptoms worsened and steroid therapy (inhalation and
oral administration) was commenced. Serum totallgE was
41.8 U/mL. Skin scratch tests against common inhalants,
such as house dust mite and fungi were negative. No other
allergic diseases were seen. The factors triggering asthma
exacerbation in this case were climate changes, exercise,
physical stress, upper respiratory tract infections (URTI) and
exposure to dust. Since 1989, the patient has been treated
with a standard regimen consisting of the regular use of
inhaled beclomethasone and oral theophylline in addition
to the use of an inhaled ~-adrenoceptor agonist on
demand and short-term oral steroids.
The clinical course is shown in Fig. 1. We used the
attack score defined by the Japanese Society of Aller-
gology to evaluate the patient's asthma symptoms.
Symptoms are divided into five grades (from cough to
severe exacerbation), each of which is given a score from
0.5 to 9. The daily attack score was indicated by the sum
of four scores recorded by the patient. Five consecutive
exacerbations were followed by serum ECp, eosinophil
counts and PEF. Blood was collected by venipuncture
using an SST tube (Becton Dickinson, Tokyo, Japan) and
was allowed to clot at room temperature for 60-120 min.
After centrifugation at 1350 9 for 10 min, serum samples
were collected and stored at -20°C. Serum ECP levels
were measured every 6 months by a radioimmunoassay
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Fig. 1 The clinical course of the patient,
showing the change in serum eosinophil
cationic protein (ECP) levels (e-e),
peripheral eosinophil counts (.--.) and
peak expiratory flow (PEF) rates (e--e).
Five consecutive exacerbations were fol-
lowed by well correlated fluctuations of
serum ECP levels that tended to elevate
even earlier than the appearance of clini-
cal symptoms. (a), (b) and (c) represent
consecutive time courses.
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(RIA)S kit (Pharmacia Upjohn, Tokyo, Japan). Serum ECP
levels correlated well with each exacerbation of the
asthma and even tended to increase before the exacer-
bations became apparent, except for the last instance, in
which oral steroid administration had commenced before
serum sampling. At the times when ECP levels were ele-
vated before exacerbations, the patient did not present
with any symptoms or only had a very mild cough. When
serum ECP levels were high, the triggering factors, such as
URTI and the inhalation of cold air, induced a burst of
asthma exacerbation. In contrast, these factors did not
precipitate exacerbations when the serum ECP levels were
low, such as during August, even if the weather was un-
stable, and at the beginning of December during a period
of URTI. Eosinophil counts were closely related to serum
ECP levels, but were dissociated in January 1993, just
before the first in a series of attacks, and in December
when the patient contracted influenza. The ECP levels
seemed to reflect the clinical course more accurately than
eosinophil counts. All exacerbations of asthma were well
resolved by short-term oral steroid therapy.
DISCUSSION
The present case demonstrated a close relationship
between serum ECP levels and asthma activity, whereas
the eosinophil counts did not always reflect the clinical
course of the asthma. In our experience with other asth-
matic patients, both serum ECP levels and blood eosino-
phil counts were higher in asthmatics compared with
levels in patients with either pulmonary emphysema or
chronic bronchitis and the serum ECP levels in asthmatics
decreased after therapy, whereas the blood eosinophil
counts did not." Several methods, including measure-
ment of PEF, pulmonary function tests, biopsy and bron-
choalveolar lavage (BAL) are considered useful for
monitoring asthma status. Pulmonary function tests and
PEF provide information regarding airway function, but
do not directly reflect the inflammatory process and may
be blunted after the use of bronchodilators. Biopsy of the
bronchial epithelium or BAL can demonstrate inflam-
mation, but these procedures are invasive and cannot be
used routinely. The total eosinophil count is a measure of
both inactive and activated cells. However, ECP is
released from activated eosinophils and it has been
shown that the serum ECP level is significantly correlated
to the level found in BAL fluid,7,8 Therefore, serum ECP is
superior to an eosinophil count of the peripheral blood as
an indicator of disease activity and response to therapy
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and is a more objective parameter of eosinophilic inflam-
mation of the lung.
It has been reported that asymptomatic asthma
patients are at risk of developing exercise-induced
asthma if their serum ECP levels are increcsed.? In a study
on childhood asthma, it was found that serum ECP levels
were higher in asymptomatic patients who developed
asthmatic symptoms after serum sampling than in those
who remained stoble.'? In the present case, serum ECP
levels tended to increase before the clinical symptoms
became apparent and the precipitating factors did not
cause exacerbation when the serum ECP levels were low.
These facts suggest that an elevated ECP level could indi-
cate a subclinical active stage that is easily converted to
acute exacerbation. Therefore, in selected cases, serum
ECP levels can reflect sub-clinically ongoing eosinophilic
inflammation of the lung and may be a practical tool for
decision making in modifying therapy when asymp-
tomatic asthma patients are encountered.
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